{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:39:51Z","timestamp":1789544391559,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,10]]},"DOI":"10.7759\/cureus.83836","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T13:38:13Z","timestamp":1746884293000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-World Outcomes of PET-Adapted Treatment for Classic Hodgkin\u2019s Lymphoma: A Study From a Single Tertiary Care Center"],"prefix":"10.7759","author":[{"given":"Imran","family":"Iftikhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Bilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Uzair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Qasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Waqas","family":"Imam Bokhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32207-8","article-title":"Classical hodgkin lymphoma","volume":"23","author":"Brice P","year":"2021","unstructured":"Brice P, de Kerviler E, Friedberg JW. Classical hodgkin lymphoma. Lancet. 2021, 23:1518-27. 10.1016\/s0140-6736(20)32207-8","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger MA","year":"2021","unstructured":"Weniger MA, K\u00fcppers R. Molecular biology of Hodgkin lymphoma. Leukemia. 2021, 35:968-81. 10.1038\/s41375-021-01204-6","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.07.002","article-title":"Hodgkin lymphoma","volume":"85","author":"Gobbi PG","year":"2013","unstructured":"Gobbi PG, Ferreri AJ, Ponzoni M, Levis A. Hodgkin lymphoma. Crit Rev Oncol Hematol. 2013, 85:216-37. 10.1016\/j.critrevonc.2012.07.002","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors JM","year":"2020","unstructured":"Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL. Hodgkin lymphoma. Nat Rev Dis Primers. 2020, 6:61. 10.1038\/s41572-020-0189-6","journal-title":"Nat Rev Dis Primers"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer DA","year":"2018","unstructured":"Eichenauer DA, Aleman BM, Andr\u00e9 M, et al.. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018, 29:iv19-29. 10.1093\/annonc\/mdy080","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson BD","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014, 32:3059-68. 10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag S","year":"2018","unstructured":"Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018, 68:116-32. 10.3322\/caac.21438","journal-title":"CA Cancer J Clin"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson P","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, et al.. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med. 2016, 374:2419-29. 10.1056\/NEJMoa1510093","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s44228-022-00008-4","article-title":"Retrospective multicenter real-life study on the first-line treatment of classical Hodgkin lymphoma in Argentina","volume":"4","author":"Mahuad C","year":"2022","unstructured":"Mahuad C, Victoria O, Laura K, et al.. Retrospective multicenter real-life study on the first-line treatment of classical Hodgkin lymphoma in Argentina. Clin Hematol Int. 2022, 4:44-51. 10.1007\/s44228-022-00008-4","journal-title":"Clin Hematol Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"27","author":"Borchmann P","year":"2024","unstructured":"Borchmann P, Ferdinandus J, Schneider G, et al.. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet. 2024, 27:341-52. 10.1016\/S0140-6736(24)01315-1","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.799948","article-title":"Real-world outcomes of Hodgkin lymphoma: a multi-centric registry from India","volume":"11","author":"Bhurani D","year":"2021","unstructured":"Bhurani D, Nair R, Rajappa S, et al.. Real-world outcomes of Hodgkin lymphoma: a multi-centric registry from India. Front Oncol. 2021, 11:799948. 10.3389\/fonc.2021.799948","journal-title":"Front Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25620","article-title":"Clinicopathological spectrum of Hodgkin's and non-Hodgkin's lymphoma: a tertiary care cancer hospital study in Pakistan","volume":"14","author":"Aslam W","year":"2022","unstructured":"Aslam W, Habib M, Aziz S. Clinicopathological spectrum of Hodgkin's and non-Hodgkin's lymphoma: a tertiary care cancer hospital study in Pakistan. Cureus. 2022, 14:e25620. 10.7759\/cureus.25620","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi200","article-title":"Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma","volume":"16","author":"Hutchings M","year":"2005","unstructured":"Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005, 16:1160-8. 10.1093\/annonc\/mdi200","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22032-3","article-title":"Interim FDG-PET\/CT for therapy monitoring and prognostication in Hodgkin's lymphoma","volume":"12","author":"Al-Ibraheem A","year":"2022","unstructured":"Al-Ibraheem A, Anwer F, Juweid ME, et al.. Interim FDG-PET\/CT for therapy monitoring and prognostication in Hodgkin's lymphoma. Sci Rep. 2022, 12:17702. 10.1038\/s41598-022-22032-3","journal-title":"Sci Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08485.x","article-title":"Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses","volume":"152","author":"Gallamini A","year":"2011","unstructured":"Gallamini A, Patti C, Viviani S, et al.. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol. 2011, 152:551-60. 10.1111\/j.1365-2141.2010.08485.x","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.5937\/smclk5-52493","article-title":"ABVD does not fit all advanced-stage classical Hodgkin lymphoma patients: real-world five-year single-center experience","volume":"17","author":"Vukovi\u0107 V","year":"2024","unstructured":"Vukovi\u0107 V, Karan-Djurasevic T, Bibic T, et al.. ABVD does not fit all advanced-stage classical Hodgkin lymphoma patients: real-world five-year single-center experience. Srpski medicinski \u010dasopis Lekarske komore. 2024, 17:5. 10.5937\/smclk5-52493","journal-title":"Srpski medicinski \u010dasopis Lekarske komore"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061760","article-title":"Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting","volume":"15","author":"Zheng S","year":"2023","unstructured":"Zheng S, Gupta K, Goyal P, et al.. Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting. Cancers (Basel). 2023, 15:10.3390\/cancers15061760","journal-title":"Cancers (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25871","article-title":"ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: results from a multicenter European study","volume":"95","author":"Mondello P","year":"2020","unstructured":"Mondello P, Musolino C, Dogliotti I, et al.. ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: results from a multicenter European study. Am J Hematol. 2020, 95:1030-7. 10.1002\/ajh.25871","journal-title":"Am J Hematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04460-9","article-title":"Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial","volume":"100","author":"Russell J","year":"2021","unstructured":"Russell J, Collins A, Fowler A, et al.. Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial. Ann Hematol. 2021, 100:1049-58. 10.1007\/s00277-021-04460-9","journal-title":"Ann Hematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2024.100790","article-title":"The impact of bleomycin deficit on survival in Hodgkin's lymphoma patients: a retrospective study","volume":"38","author":"Soldi LR","year":"2024","unstructured":"Soldi LR, Rabelo DH, da Silva PH, Silva VL, Silva MJ. The impact of bleomycin deficit on survival in Hodgkin's lymphoma patients: a retrospective study. Cancer Treat Res Commun. 2024, 38:100790. 10.1016\/j.ctarc.2024.100790","journal-title":"Cancer Treat Res Commun"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134588","article-title":"Real life treatment alterations of frontline therapies in classic Hodgkin's lymphoma","volume":"5","author":"Al Hadidi S","year":"2020","unstructured":"Al Hadidi S, Nair R, Steiner RE, et al.. Real life treatment alterations of frontline therapies in classic Hodgkin's lymphoma. Blood. 2020, 5:23-4. 10.1182\/blood-2020-134588","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/356637-real-world-outcomes-of-pet-adapted-treatment-for-classic-hodgkins-lymphoma-a-study-from-a-single-tertiary-care-center","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T13:38:14Z","timestamp":1746884294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/356637-real-world-outcomes-of-pet-adapted-treatment-for-classic-hodgkins-lymphoma-a-study-from-a-single-tertiary-care-center"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.83836","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,10]]}}}